Press releases

August 3, 2023

AAHI Receives $18 Million Award to Develop a Temperature Stable, Single-Dose Chikungunya RNA Vaccine Through a Phase 1 Clinical Trial

Read More
May 31, 2023

AAHI Presents Advancements In Vaccine Formulations and Methodology at MVADS Conference 2023

Read More
March 6, 2023

AAHI Reports Encouraging Results of First-In-Human Trial of Its Temperature-Stable Tuberculosis Vaccine Candidate

Read More
February 15, 2023

AAHI Announces $3M Award to Develop an Intranasal Pan-Viral Countermeasure against Respiratory Viruses

Read More
February 6, 2023

AAHI Announces $9.9M Award to Develop a Nasal Spray Influenza RNA Vaccine Through Phase 1 Clinical Trials

Read More
November 2, 2022

AAHI Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature

Read More

Page [tcb_pagination_current_page] of [tcb_pagination_total_pages]